Cowen Downgrades Regulus Therapeutics (RGLS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- FedEx pilots ratify new collective bargaining agreement
- The real reason Meta shares are surging has nothing to do with its new AI model
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Regulus Therapeutics (RGLS) Tops Q3 EPS by 3c
November 1, 2016 4:11 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $1.2 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More